AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 241 min read$TNGX

Newcomb Jessica sold $199K of TNGX

Newcomb Jessica (Principal Accounting Officer) sold 8,200 shares of Tango Therapeutics, Inc. (TNGX) at an average of $24.22 ($22.80–$25.17, $0.20M total) across 3 trades on 2026-09-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Newcomb Jessica
Published Sep 24, 2026, 11:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 12:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TNGX
Neutral
medium confidence
Mentioned
$TNGX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TNGXNeutralLow
01

Why it matters

The disclosed sale is routine and unlikely to move the stock significantly.

02

Market read

Minor insider sale with limited trading impact.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 5/10Timing: filing date 2026-09-24

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$TNGXNeutralMedium confidence
Context

Principal Accounting Officer sold 8,200 shares for $198.6K via a 10b5-1 plan, reducing her stake to 59,121 shares.

Expected impact

Potential slight downward pressure in the short term, likely limited to a few basis points.

Evidence & confidence

A $199K sale by a senior officer is routine and below materiality thresholds; markets typically react modestly to such disclosures.

Market effects

Sector

No broader sector impact; the sale is company‑specific.

Regional

Limited to investors tracking Tango Therapeutics.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The sale could be a strategic rebalancing rather than a lack of confidence.

Key entities

  • Officer
    Newcomb Jessica

    Principal Accounting Officer of Tango Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TNGX insider trading history →

Related articles

SEP 3
$TNGXMedAI 8/10

Tangram Therapeutics PLC: Tangram Therapeutics Announces Progression to Patient Cohorts in Phase 1/2 RESTORE-MASH Trial of TGM-312 and Appointment of Dr Sonya Montgomery as Chief Development Officer

Tangram Therapeutics announced its MASH treatment TGM-312 has progressed to patient cohorts in a Phase 1/2 trial. The company also appointed Dr. Sonya Montgomery as Chief Development Officer. TGM-312 targets liver inflammation and steatosis, with interim data expected in 2027. Dr. Montgomery brings 25 years of experience in clinical development.

finanznachrichten.de2 min
AUG 11
$TNGXMed

Why is Tango Therapeutics stock sliding today?

Tango Therapeutics (TNGX) shares fell about 4% to $26.58 after Q2 2026 results missed expectations. Net loss widened to $0.37 per share versus $0.35 a year earlier, above the ~$0.32 consensus. The quarter again had zero revenue. General and administrative expenses nearly doubled to $22.6M from $11.3M, driven by personnel and share-based comp.

investing.com4 min
AUG 11
$TNGXMed

Tango Therapeutics Reports Second Quarter 2026 Financial Results

Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 da

SEC EDGAR 8-K4 min
JUL 15
$TNGXMed

Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues

Canaccord Genuity raised its price target for Tango Therapeutics (NASDAQ:TNGX) to $46 from $42 and kept a Buy rating, citing a revised model that includes combined revenues from vopimetostat plus KRAS inhibitors in NSCLC. Jefferies upgraded TNGX to Buy and lifted its target to $60. Tango also signed an underwriting for about 18.2M shares plus pre-funded warrants, expecting ~$566.5M net proceeds for trials and R&D.

yahoo.com5 min